Pfizer Is Sending Ginkgo Bioworks (DNA) Stock Higher: Here's Why
Portfolio Pulse from Adam Eckert
Ginkgo Bioworks Holdings (DNA) announced a collaboration with Pfizer (PFE) for the discovery of RNA-based drug candidates. Pfizer will use Ginkgo's RNA technology for novel RNA molecule discovery and development. Ginkgo will receive an upfront payment and could receive up to $331 million in fees and milestone payments across three planned programs, along with potential royalties on future sales.
September 27, 2023 | 1:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ginkgo Bioworks' collaboration with Pfizer could lead to significant financial gains, boosting its stock.
The partnership with Pfizer, a major pharmaceutical company, is a significant development for Ginkgo Bioworks. The potential financial gains from this collaboration, including an upfront payment and up to $331 million in fees and milestone payments, are likely to have a positive impact on Ginkgo's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Pfizer's collaboration with Ginkgo Bioworks could lead to the discovery of novel RNA-based drug candidates, potentially boosting its stock.
The collaboration with Ginkgo Bioworks could enhance Pfizer's capabilities in RNA-based drug discovery and development. This could potentially lead to the discovery of novel treatments, which would likely have a positive impact on Pfizer's stock in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80